drugset / Trial / NCT00200434

A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension

NCT00200434

Phase 3 Completed 600 enrolled Mylan Bertek Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to contrast the efficacy and safety of 3 dose levels of nebivolol vs. placebo, when added to a patient's existing antihypertensive medication(s) for 3 months, in patients with mild to moderate hypertension

Timeline

Start
2002-10
Primary completion
Completion
2003-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Nebivolol Other / unclassified

Indications